With the other COVID-19 vaccines in Europe focused on the virus’s spike protein, this shot could protect against variants that might compromise others, making it the perfect booster.
For Suzi Ring's latest contributions to The Japan Times, see below:
U.S. trial data showing the firm's shot to be highly effective was a welcome reprieve this week, but the good news lasted less than a day.
Both sides have blamed each other for export curbs and nationalism, posing a risk to the fragile post-Brexit trade relationship agreed on only in December.
Dangerous coronavirus variants are carpeting the globe, pushing scientists in the U.K. and elsewhere to target multiple versions of the pathogen in a single shot.
What began as a bid to bring transparency has spiraled into chaotic mud-slinging that some fear could spur a trade row amid the pandemic.
The root of the dispute is Astra’s decision to prioritize the U.K. over the EU following a Belgian production glitch, in what Brussels claims to be a breach of contractual commitments.
AstraZeneca PLC and the University of Oxford’s Covid-19 vaccine won U.K. clearance, marking the first approval worldwide for a shot that will be key to mass immunizations.
Long-haulers — survivors of COVID-19 left with debilitating conditions — represent another insidious dimension of the pandemic.